Search details
1.
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
N Engl J Med
; 389(3): 228-238, 2023 Jul 20.
Article
in English
| MEDLINE | ID: mdl-37467498
2.
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human.
Drug Metab Dispos
; 50(6): 781-797, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34154993
3.
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
Antimicrob Agents Chemother
; 61(1)2017 01.
Article
in English
| MEDLINE | ID: mdl-27795368
4.
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Br J Clin Pharmacol
; 81(5): 918-28, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26659791
5.
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Arthritis Rheum
; 65(4): 1011-21, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23400715
6.
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
Antimicrob Agents Chemother
; 57(12): 6147-53, 2013 Dec.
Article
in English
| MEDLINE | ID: mdl-24080653
7.
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
Invest New Drugs
; 31(1): 77-84, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-22370972
8.
Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
Pulm Pharmacol Ther
; 26(6): 666-71, 2013 Dec.
Article
in English
| MEDLINE | ID: mdl-23523663
9.
Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
CPT Pharmacometrics Syst Pharmacol
; 12(6): 842-852, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36883675
10.
Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria.
Clin Pharmacokinet
; 62(1): 89-99, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36633811
11.
Quantification of oxalate by novel LC-MS/MS: assay development, validation and application in lumasiran clinical trials.
Bioanalysis
; 15(9): 481-491, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37195004
12.
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Clin Pharmacokinet
; 62(10): 1509-1522, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37639169
13.
Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.
Antimicrob Agents Chemother
; 56(9): 4927-36, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-22802243
14.
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Ann Rheum Dis
; 70(11): 1905-13, 2011 Nov.
Article
in English
| MEDLINE | ID: mdl-21798883
15.
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.
BMC Pulm Med
; 11: 14, 2011 Feb 28.
Article
in English
| MEDLINE | ID: mdl-21356110
16.
Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
JIMD Rep
; 57(1): 85-93, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33473344
17.
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection.
Drugs R D
; 21(4): 455-465, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34741731
18.
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Clin Pharmacokinet
; 60(3): 365-378, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33047216
19.
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Clin Pharmacol Ther
; 110(5): 1250-1260, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34510420
20.
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Clin Pharmacol Ther
; 109(2): 372-382, 2021 02.
Article
in English
| MEDLINE | ID: mdl-32599652